Opinion|Videos|January 31, 2025
The Inflation Reduction Act and Cost Considerations for BTK Inhibitors
Panelists discuss how the inclusion of ibrutinib on the Inflation Reduction Act (IRA) negotiated drug price list could make it a more economically attractive first-line option, potentially influencing the sequencing of Bruton tyrosine kinase (BTK) inhibitors in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) treatment while considering other financial factors like insurance coverage, copays, and total out-of-pocket costs that impact patient access and treatment decisions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- With ibrutinib on the negotiated drug price list under the IRA, how might cost considerations influence first-line BTK inhibitor selection and subsequently shape second-line and beyond treatment choices in R/R CLL?
- Beyond the IRA, what role do broader economic factors, such as insurance coverage and out-of-pocket costs, play in treatment selection for patients with R/R CLL requiring BTK inhibitors?
Advertisement
Related to this article
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
Preparing Practices for the Next Era of Hepatitis B Care
4
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
5